Managing unsold stock that crosses its expiration date represents an everyday operational reality for chemists, stockists, and pharmaceutical manufacturers. In practice, retail pharmacies bundle expired formulations, returning them backward through wholesale distributors to the original manufacturing plant. Because medicine formulations cannot legally be re-sold once expired, handling tax invoices, credit notes, and input tax credit reversals demands strict adherence to statutory rules.
Statutory framework under Section 17(5)(h) and Section 34
The statutory basis for input tax credit eligibility begins with Section 16(1) of the CGST Act, allowing credit on supplies used in the furtherance of business. However, Section 17(5)(h) of the CGST Act imposes a non-negotiable block on credits. It establishes that input tax credit shall not be available in respect of:
“goods lost, stolen, destroyed, written off or disposed of by way of gift or free samples” Section 17(5)(h), CGST Act
When expired pharmaceuticals arrive at a plant and undergo incineration or bio-chemical destruction, they become destroyed goods under the law. Consequently, the input tax credit associated with them cannot be retained in the taxpayer ledger. In parallel, Section 34(1) and Section 34(2) govern how suppliers issue credit notes and adjust their output tax liability, setting a strict time limit linked to 30 November following the end of the financial year.
To clarify how these statutory sections apply to pharmaceutical supply chains, the CBIC issued detailed administrative guidance in Circular No. 72/46/2018-GST (dated 26 October 2018). The circular outlines two alternative procedures for returning time-expired goods.
Option 1: return treated as a fresh supply
Under this option, the customer returning the expired medicines treats the return movement as an ordinary outward supply and issues a tax invoice:
- Registered dealer return: If the returning party (retailer or wholesaler) is a regular registered taxpayer, they issue a fresh tax invoice for the return supply. The value shown on the original procurement invoice can serve as the value of the return invoice.
- ITC entitlement for recipient: The recipient of this return supply (the distributor or manufacturer) can claim input tax credit on this invoice, subject to normal eligibility rules under Section 16 of the CGST Act.
- Composition taxpayers and unregistered persons: If the returning chemist is registered under the composition scheme, they issue a bill of supply with composition tax, meaning no ITC is available to the recipient. If unregistered, the goods move under a commercial transport document without GST.
- Destruction by the manufacturer: When the manufacturer finally destroys the returned medicines, they must reverse input tax credit under Section 17(5)(h). Under Option 1, the amount to reverse is the exact ITC availed on the fresh return invoice, not the original manufacturing input costs.
Common mistake: Attempting to trace five-year-old packaging and active pharmaceutical ingredient batches when using Option 1. The circular explicitly confirms that under the fresh supply route, the manufacturer simply reverses the ITC claimed on the inward return invoice received from the distributor.
Option 2: return via delivery challan and credit note
Option 2 maintains the historical sales trail through credit notes issued by the original seller:
- Delivery challan movement: The retailer or wholesaler returns expired stock using a delivery challan under Rule 55 of the CGST Rules, without issuing a fresh tax invoice.
- Issuance of credit note: The manufacturer or wholesaler who originally supplied the stock issues a GST credit note under Section 34(1).
- Time limit for tax adjustment: Under Section 34(2), the supplier can adjust their output tax liability only if the credit note is issued on or before 30 November following the end of the financial year in which the original supply occurred, or the date of filing the annual return. Crucially, the recipient must have reversed their corresponding ITC.
- Lapsed time limit (commercial credit note): If the statutory deadline has expired, the supplier can still issue a financial or commercial credit note to settle ledger balances. However, no GST adjustment can be claimed, and the credit note is not declared on the GST common portal.
- Reversal on destruction: When the manufacturer destroys the batch, they must reverse the ITC attributable to the actual manufacture of those medicines under Section 17(5)(h). This includes credit claimed on active pharmaceutical ingredients, excipients, and packing materials.
Notice risk: Adjusting GST on credit notes issued past 30 November triggers mismatch notices. Rule 88D flags such differences, and authorities demand repayment along with 18% annual interest under Section 50 of the CGST Act.
Worked scenario: pharmaceutical return and destruction
Consider Serum Remedies Private Limited, a drug formulation manufacturer based in Baddi, Himachal Pradesh. In August 2024, Serum Remedies sold 1,000 strips of antibiotic capsules (Batch No. AB-402) to Mediline Distributors in Delhi at ₹120 per strip, charging 12% GST (₹14.40 per strip). Mediline distributed the batch to retail pharmacies.
In October 2026, 200 strips remain unsold and reach their stated expiry date. Mediline collects the 200 strips from retail outlets and processes the return to Serum Remedies. The financial impact differs depending on whether Option 1 or Option 2 is selected.
| Compliance parameter | Option 1 (fresh return invoice) | Option 2 (Section 34 credit note) |
|---|---|---|
| Transit documentation | Tax invoice issued by Mediline | Delivery challan under Rule 55 |
| Taxable value of 200 strips | ₹24,000 (at ₹120 per strip) | ₹24,000 (original invoice rate) |
| GST charged or credited (12%) | ₹2,880 (IGST charged by Mediline) | ₹2,880 (credit note issued by Serum) |
| Can supplier adjust tax liability? | Not applicable (Mediline pays outward tax) | No (financial year 2024-25 deadline lapsed) |
| Serum Remedies inward ITC claimed | ₹2,880 claimed upon receiving invoice | ₹0 (commercial credit note, no tax adjust) |
| Manufacturer ITC reversed on destruction | ₹2,880 (inward return invoice ITC) | ₹1,440 (attributable raw material ITC) |
In Option 1, Mediline issues an invoice for ₹24,000 plus ₹2,880 IGST. Serum Remedies claims ₹2,880 in Table 4(A)(5) of Form GSTR-3B upon receiving the goods. When Serum Remedies incinerates the batch in November 2026, it reverses ₹2,880 under Section 17(5)(h). The tax impact on Serum Remedies nets to zero.
In Option 2, because the original supply occurred in FY 2024-25, the statutory deadline of 30 November 2025 has passed. Serum Remedies issues a commercial credit note for ₹24,000 without tax adjustment. Mediline keeps the stock credit in its financial ledger. When Serum Remedies incinerates the batch, its cost accountants calculate that active ingredients and foil packing for 200 strips consumed ₹1,440 of original input tax credit. Serum Remedies must reverse ₹1,440 in cash or credit.
Reporting reversals in Form GSTR-3B
Reporting accuracy in monthly returns ensures your ledger aligns with portal records and prevents unexpected scrutiny:
- Permanent reversal in Table 4(B)(1): Reversals under Section 17(5)(h) are permanent and cannot be re-claimed in subsequent tax periods. As outlined in official GSTN Form GSTR-3B instructions, permanent statutory reversals must be entered in Table 4(B)(1) (“As per rules 38, 42 and 43 of CGST Rules and Section 17(5)”).
- Distinction from Table 4(B)(2): Table 4(B)(2) is reserved for temporary, re-claimable reversals, such as unpaid vendor supplies under Rule 37. Never park Section 17(5)(h) destruction reversals in Table 4(B)(2).
- Reconciliation against GSTR-2B: For Option 1, verify that Mediline's return invoice appears in your GSTR-2B before availing the credit in Table 4(A)(5). This step maintains compliance under Section 16(2)(aa).
For broader guidelines on input tax credits and statutory blocks, consult our guides on ITC claim rules under GST, blocked credit under GST Section 17(5), and our detailed analysis of GSTR-2B credit note reconciliation.
Practical checkpoints for pharma accounting teams
- Maintain incineration certificates: Whenever expired stock is destroyed, document the event with destruction memos, waste management vendor slips, and internal quality audit sign-offs.
- Tag batches in ERP systems: Record batch numbers, manufacturing dates, and original invoice references in SAP, Marg, or Tally Prime to support cost allocations if Option 2 is audited.
- Watch annual return deadlines: For Option 2 credit notes, track the 30 November cut-off date vigilantly to ensure eligible GST credit notes are reported before liability adjustments lapse.
- Reconcile inward credit notes monthly: Compare vendor credit notes against portal records between the 14th and the 20th to catch any unilateral adjustments by distributors.
Related guides
- ITC reversal on goods sent for exhibition abroad not sold: GST rules and Circular 108
- ITC on free replacement warranty goods: Circular 195 explained
- ITC reversal on sale of used business vehicle: margin scheme versus Section 18(6)
- Post supply discount ITC reversal commercial credit note
Frequently asked questions
What are the two options for returning expired medicines under GST?
Under CBIC circular guidance in Circular No. 72/46/2018-GST (dated 26 October 2018), taxpayers have two options. Option 1 treats the return as a fresh outward supply on a tax invoice. Option 2 treats the return via delivery challan with the supplier issuing a GST credit note under Section 34(1).
Must a pharmaceutical manufacturer reverse ITC when expired medicines are destroyed?
Yes. Under Section 17(5)(h) of the CGST Act, ITC must be reversed when goods are destroyed. Under Option 1 (fresh return supply), the manufacturer reverses the ITC claimed on the inward return invoice. Under Option 2 (credit note route), the manufacturer reverses the ITC attributable to raw materials and packing used to manufacture those destroyed goods.
Can a supplier adjust tax liability if a credit note is issued after 30 November?
No. Under Section 34(2) of the CGST Act, GST liability adjustments can only occur up to 30 November following the end of the financial year, or the annual return filing date. If expired goods return after this deadline, the supplier issues a commercial credit note without tax adjustment, meaning no portal declaration is needed.
Where is the expired medicine ITC reversal reported in Form GSTR-3B?
Permanent reversals under Section 17(5)(h) for destroyed medicines must be declared in Table 4(B)(1) of Form GSTR-3B. If a recipient reverses temporary credit while awaiting vendor reconciliation, that temporary entry is shown in Table 4(B)(2).
Reconcile pharmaceutical inward invoices and credit notes
Handling medical returns alongside regular stock requires continuous matching between your purchase register and GSTR-2B. gstr2bmatch.in identifies missing invoices, mismatched tax values, and pending credit notes across hundreds of suppliers in seconds. Your GSTR-2B and purchase register files are read in your browser and never uploaded to any server.
Last checked: 14 October 2026. Sources: Section 17(5)(h), CGST Act, CBIC Circular No. 72/46/2018-GST, GSTN GSTR-3B user manual.